Comprehensive data for studying serum exosome microRNA transcriptome in Parkinson's disease patients

被引:0
|
作者
Yu, Zhiyang [1 ]
Saiki, Shinji [1 ,2 ]
Shiina, Kenta [1 ]
Iseki, Tatou [1 ]
Sasazawa, Yukiko [1 ,3 ,4 ]
Ishikawa, Kei-Ichi [1 ]
Nishikawa, Noriko [1 ]
Sako, Wataru [1 ]
Oyama, Genko [1 ]
Hatano, Taku [1 ]
Suzuki, Ayami [1 ,2 ]
Souma, Sanae [1 ]
Kataura, Tetsushi [2 ]
Hattori, Nobutaka [1 ,3 ,4 ,5 ]
机构
[1] Juntendo Univ, Grad Sch Med, Dept Neurol, Tokyo, Japan
[2] Univ Tsukuba, Inst Med, Dept Neurol, Ibaraki, Japan
[3] Juntendo Univ, Fac Med, Div Dev Autophagy Modulating Drugs, Tokyo, Japan
[4] Juntendo Univ, Grad Sch Med, Res Inst Dis Old Age, Tokyo, Japan
[5] RIKEN Ctr Brain Sci, Neurodegenerat Disorders Collaborat Lab, Saitama, Japan
关键词
DELAYED-START TRIAL; ENRICHMENT ANALYSIS; ALPHA-SYNUCLEIN; DOUBLE-BLIND; MIRNAS; RASAGILINE; EXPRESSION; HALLMARKS;
D O I
10.1038/s41597-024-03909-6
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Parkinson's disease (PD), the second most prevalent neurodegenerative disorder, was classically attributed to alpha-synuclein aggregation and consequent loss of dopaminergic neurons in the substantia nigra pars compacta. Recently, emerging evidence suggested a broader spectrum of contributing factors, including exosome-mediated intercellular communication, which can potentially serve as biomarkers and therapeutic targets. However, there is a remarkable lack of comprehensive studies that connect the serum exosome microRNA (miRNA) transcriptome with demographic, clinical, and neuroimaging data in PD patients. Here, we present serum exosome miRNA transcriptome data generated from four cohort studies. Two of these studies include 96 PD patients and 80 age- and gender-matched controls, with anonymised demographic, clinical, and neuroimaging data provided for PD patients. The other two studies involve 96 PD patients who were evaluated both before and after one year of treatment with rasagiline, a widely prescribed anti-parkinsonism drug. Together, the datasets provide a valuable source for understanding pathogenesis and discovering biomarkers and therapeutic targets in PD.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Studying risk factors for Parkinson's disease
    Bornebroek, M
    Breteler, M
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2003, 18 (12) : 1113 - 1114
  • [32] Proteomic approach to studying Parkinson's disease
    Zhang, J
    Goodlett, DR
    MOLECULAR NEUROBIOLOGY, 2004, 29 (03) : 271 - 288
  • [33] Serum homocysteine and physical exercise in patients with Parkinson's disease
    Crispim Nascimento, Carla Manuela
    Stella, Florindo
    Garlipp, Celia Regina
    Santos, Ruth Ferreira
    Gobbi, Sebastiao
    Bucken Gobbi, Lilian Teresa
    PSYCHOGERIATRICS, 2011, 11 (02) : 105 - 112
  • [34] Serum level of inflammatory factors in patients with Parkinson's disease
    Szlufik, S.
    Koziorowski, D.
    Tomasiuk, R.
    Friedman, A.
    MOVEMENT DISORDERS, 2012, 27 : S495 - S495
  • [35] Decreased serum proNGF concentration in patients with Parkinson’s disease
    Xiao-Min Xu
    Mei-Xue Dong
    Xia Feng
    Yang Liu
    Jun-Xi Pan
    Shi-Yu Jia
    Du Cao
    You-Dong Wei
    Neurological Sciences, 2018, 39 : 91 - 96
  • [36] Oxidative and nitrosative stress in serum of patients with Parkinson’s disease
    Hikmet Can Çubukçu
    Mustafa Yurtdaş
    Zahide Esra Durak
    Bilal Aytaç
    Hafize Nalan Güneş
    Burcu Gökçe Çokal
    Tahir Kurtuluş Yoldaş
    İlker Durak
    Neurological Sciences, 2016, 37 : 1793 - 1798
  • [37] Serum ceruloplasmin and ferritin levels in patients with Parkinson's disease
    Rohani, M.
    Jalali, N.
    Khademolhosseini, M.
    Miri, S.
    Shahidi, G. A.
    Ghourchian, S.
    MOVEMENT DISORDERS, 2013, 28 : S319 - S319
  • [38] Serum amino acid profile in patients with Parkinson's disease
    Figura, Monika
    Kusmierska, Katarzyna
    Bucior, Ewelina
    Szlufik, Stanislaw
    Koziorowski, Dariusz
    Jamrozik, Zygmunt
    Janik, Piotr
    PLOS ONE, 2018, 13 (01):
  • [39] EVALUATION OF SERUM HEPCIDIN CONCENTRATIONS IN PARKINSON'S DISEASE PATIENTS
    Manolov, V.
    Hadjidekova, S.
    Petrova, J.
    Vasilev, V.
    Petrova, M.
    Kunchev, T.
    Jelev, Y.
    Jeliazkov, P.
    Gramatikova, Z.
    Voleva, S.
    Tzatchev, K.
    Traykov, L.
    PARKINSONISM & RELATED DISORDERS, 2018, 46 : E74 - E75
  • [40] Serum uric acid concentration, in patients with Parkinson's disease
    Iwasaki, Y.
    Kawabe, K.
    Kano, O.
    Yoshii, Y.
    Ikeda, K.
    MOVEMENT DISORDERS, 2009, 24 : S527 - S527